2025
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
Warren R, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal Of Dermatology 2025, ljaf032. PMID: 39862230, DOI: 10.1093/bjd/ljaf032.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsOpen-label extensionComplete skin clearanceIL-17APlaque psoriasisSkin clearanceIL-17FRates of treatment-emergent adverse eventsTreatment-emergent adverse event ratesModerate to severe plaque psoriasisOpen-label extension periodSafety of bimekizumabUpper respiratory tract infectionDouble-blind periodSevere plaque psoriasisInterleukin (IL)-17ARespiratory tract infectionsYear of treatmentLong-term resultsInflammatory bowel diseaseMonoclonal IgG1 antibodyOral candidiasisClinical responseMaintenance doseTract infections
2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry
Silverberg J, Calimlim B, Grada A, Bunick C, Gooderham M, Shi V, Obi C, Knapp K, Munoz B, Crawford J, Paller A. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. Journal Of Dermatological Treatment 2024, 35: 2428729. PMID: 39662888, DOI: 10.1080/09546634.2024.2428729.Peer-Reviewed Original ResearchReal-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of ADSwitching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study
Bunick C, Magnolo N, Moore A, Xinghua G, Lynde C, Ibrahim N, Grada A, Levy G, Calimlim B, Wu X, Armendariz Y, Eyerich K. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal Of Cutaneous Medicine 2024, 8: s451. DOI: 10.25251/skin.8.supp.451.Peer-Reviewed Original ResearchAtopic dermatitisSafety resultsInadequate responseEczema Area and Severity IndexWeeks post-switchEczematous skin lesionsOral Janus kinaseEffective treatment strategiesClinically meaningful improvementsClinically meaningful outcomesJanus kinaseChronic skin diseaseOptimal treatment targetsClinical responseMonotherapy studiesSkin clearanceSafety profileDupilumabTreatment strategiesInterleukin-13Interleukin-4UpadacitinibSafety signalsSwitch groupInterleukin-13 signalingWhy Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry
Silverberg J, Bunick C, Calimlim B, Grada A, Knapp K, Munoz B, Crawford J, Obi C, Paller A. Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s461. DOI: 10.25251/skin.8.supp.461.Peer-Reviewed Original ResearchPatient-reported outcomesTreat-to-target recommendationsSkin clearanceAtopic dermatitisOptimal treatmentSkin severityNRS-sleepSkin lesionsNRS painOptimal patient outcomesPartial improvementPatient outcomesNear-complete resolutionAtopic dermatitis treatmentReal-world studyMinimal itchingVIGA-ADOptimal treatment targetsEczema/atopic dermatitisDLQI 0/1Logistic regression modelsCross-sectional analysisItch severityOdds ratioDermatitis treatmentMatching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2024, 14: 3071-3081. PMID: 39453596, PMCID: PMC11557788, DOI: 10.1007/s13555-024-01293-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSkin clearanceIndirect comparisonsStatic Physician's Global AssessmentRisankizumab-treated patientsPhysician global assessmentTreatment of psoriasisMatching-adjusted indirect comparisonIndividual patient dataLife Quality IndexPlaque psoriasisPsoriasis AreaRisankizumabDeucravacitinibNew therapiesIntroductionDespite advancesPsO.Global assessmentQuality of lifePsoriasisPatientsPropensity scorePatient dataClearanceHealthcare providers706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.Peer-Reviewed Original ResearchPatient support programAtopic dermatitisItch improvementSkin clearanceOral Janus kinase inhibitorPatient experiencePhase 3 clinical trialsTreating moderate-to-severe ADEffect of upadacitinibMultiple phase 3 clinical trialsModerate-to-severe ADJanus kinase inhibitorsClinical trial resultsPatient-reported experiencesDecreased quality of lifeEvaluate patient experiencePatient-reported outcomesTopical corticosteroidsPatient ageCross-sectional analysisQuality of lifeUpadacitinib dosesKinase inhibitorsUpadacitinibTreatment durationBimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials
Han G, Gottlieb A, Armstrong A, Strober B, Soung J, Herr H, Davis L, Lebwohl M. Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s369. DOI: 10.25251/skin.8.supp.369.Peer-Reviewed Original ResearchOpen-label extensionSevere plaque psoriasisPASI responseBaseline PASIPlaque psoriasisSkin clearanceModerate to severe plaque psoriasisInhibits interleukin (IL)-17FLevels of skin clearanceDouble-blind periodPhase 3b trialPhase 3 trialProportion of patientsInterleukin (IL)-17FAssociated with improved quality of lifeMonoclonal IgG1 antibodyHigher PASIMaintenance dosePsoriasis AreaBimekizumabAssociated with improved qualityPooled analysisPASIPatientsQuality of life
2023
44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Photowala H, Patel M, Garg V, Strober B. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 89: ab62. DOI: 10.1016/j.jaad.2023.07.251.Peer-Reviewed Original ResearchAbrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin‐Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Johnson S, Farooqui S, Kerkmann U, Clibborn C. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 2056-2066. PMID: 37335885, DOI: 10.1111/jdv.19280.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsSevere atopic dermatitisSerious treatment-emergent adverse eventsPhase 3 studyAtopic dermatitisSafety profileAbrocitinib 200Frequent treatment-emergent adverse eventsLong-term extension studyUpper respiratory tract infectionLong-term safety profileChronic atopic dermatitisManageable safety profileProportion of patientsRespiratory tract infectionsFull treatment periodLong-term efficacyLong-term safetyPruritus improvementSkin clearanceEfficacy endpointSafety endpointAdverse eventsTract infectionsAD trialsBimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober B, Paul C, Blauvelt A, Thaçi D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez N, Eyerich K. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2023, 89: 486-495. PMID: 37182701, DOI: 10.1016/j.jaad.2023.04.063.Peer-Reviewed Original ResearchConceptsOpen-label extensionPASI 100 responseSevere plaque psoriasisWeek 96Plaque psoriasisWeek 48Common adverse eventsComplete skin clearanceDouble-blinded periodPhase 3b trialUrinary tract infectionTreatment of psoriasisMonoclonal IgG1 antibodySecukinumab patientsSkin clearanceAdverse eventsTract infectionsMore patientsSafety profilePhase 3bBimekizumabOral candidiasisSafety dataPatientsIgG1 antibodies
2022
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis G, Warren R, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal Of Dermatology 2022, 188: 330-340. PMID: 36751950, DOI: 10.1093/bjd/ljac089.Peer-Reviewed Original ResearchConceptsExposure-adjusted incidence ratesTreatment-emergent adverse eventsAdverse eventsDurable improvementMajority of TEAEsDiscontinuation of biologicsNew safety findingsPASI 90 respondersSevere plaque psoriasisHealth-related qualityBody surface areaTime of switchAbsolute PASIIIIb trialPASI 100PASI 90Skin clearancePlaque psoriasisWeek 48Clinical responseEfficacy outcomesPsoriasis AreaSafety findingsWeek 24Week 5234820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Strober B. 34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab200. DOI: 10.1016/j.jaad.2022.06.833.Peer-Reviewed Original ResearchSuper‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance
Reich K, Gordon K, Strober B, Langley R, Miller M, Yang Y, Shen Y, You Y, Zhu Y, Foley P, Blauvelt A. Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal Of The European Academy Of Dermatology And Venereology 2022, 36: 2393-2400. PMID: 35920762, DOI: 10.1111/jdv.18474.Peer-Reviewed Original ResearchConceptsGlobal assessment scoreInvestigator's Global Assessment scoreSevere psoriasisGuselkumab treatmentChronic immune-mediated inflammatory skin diseaseBody weightImmune-mediated inflammatory skin diseaseAssessment scoresStepwise logistic regression analysisBaseline Psoriasis AreaComplete skin clearanceEarly clinical responseLess obese patientsVOYAGE 2 studiesBaseline body weightSubset of patientsInflammatory skin diseaseLogistic regression analysisHuman monoclonal antibodyPASI 100PASI 75Skin clearanceBaseline characteristicsBaseline demographicsClinical responseDeucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaçi D, Strober B, Gordon K, Foley P, Gooderham M, Morita A, Papp K, Puig L, Menter M, Colombo M, Elbez Y, Kisa R, Ye J, Napoli A, Wei L, Banerjee S, Merola J, Gottlieb A. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology And Therapy 2022, 12: 495-510. PMID: 35025062, PMCID: PMC8850503, DOI: 10.1007/s13555-021-00649-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSevere plaque psoriasisPhase 2 trialPlaque psoriasisStatic Physician's Global AssessmentBody surface area involvementGlobal assessmentPhase 2 clinical trialLife outcomesComplete skin clearanceMethodsPost-hoc analysisPhysician global assessmentSurface area involvementNew oral therapiesLife Quality IndexMost efficacy measuresPromising new oral therapyGreater improvementSkin clearanceSevere psoriasisOral therapyPsoriasis AreaInvestigator assessmentClinical outcomesWeek 12
2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich K, Warren R, Lebwohl M, Gooderham M, Strober B, Langley R, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A. Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal Of Medicine 2021, 385: 142-152. PMID: 33891380, DOI: 10.1056/nejmoa2102383.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisWeek 48Week 16Bimekizumab groupSecukinumab groupPASI scoreInterleukin-17AOral candidiasisGreater skin clearanceInterleukin-17 inhibitorsPASI 100 responsePhase 3b trialSafety of bimekizumabPrimary end pointSeverity Index scoreMonoclonal IgG1 antibodySkin clearanceSevere psoriasisPsoriasis AreaLarge trialsBimekizumabSecukinumabWeek 4Patients
2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
Elewski B, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober B. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal Of Dermatological Treatment 2017, 28: 492-499. PMID: 28266243, DOI: 10.1080/09546634.2017.1294727.Peer-Reviewed Original ResearchConceptsQuality of lifeSeverity Index (PASI) 90 responseDLQI 0/1 responsePASI 75Skin clearancePASI 90Psoriasis AreaDermatology Life Quality Index responseGreater health-related qualityPatients' QOLGreater skin clearancePhase 3 studyHealth-related qualityNew biological therapiesRelevant therapeutic goalSevere psoriasisWeek 52Psoriasis patientsBiological therapyWeek 12Therapeutic goalsTrial dataSustained levelsIgA resultsClearance
2016
Clinical meaningfulness of complete skin clearance in psoriasis
Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. Journal Of The American Academy Of Dermatology 2016, 75: 77-82.e7. PMID: 27206759, DOI: 10.1016/j.jaad.2016.03.026.Peer-Reviewed Original ResearchConceptsComplete skin clearanceSkin clearancePASI 100Score 0Dermatology Life Quality IndexNew psoriasis therapiesPsoriasis Symptom InventoryTotal skin clearancePercentage of patientsPhase III trialsHealth-related qualityLife Quality IndexMeaningful end pointsPASI 75PASI 90Psoriasis symptomsPsoriasis therapyTreatment responsePatient's perspectiveInsufficient evidenceClinical meaningfulnessPatientsEnd pointSymptom InventoryClearance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply